Reduced expression of transforming growth factor-β1 and correlated elevation of interleukin-17 and interferon-γ in pediatric patients with chronic primary immune thrombocytopenia (ITP)

Pediatric Blood and Cancer

Volumn 57, Issue 4, 2011, Pages 636-640

  Wang, Jiaan Der ^a,b   Chang, Te Kau ^a   Lin, Heng Kuei ^a   Huang, Fang Liang ^a   Wang, Chau Jong ^b   Lee, Huei Jane ^b  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chronic primary immune thrombocytopenia; Cytokines; IL 17; T helper cells; TGF 1

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ARTICLE; BLOOD LEVEL; CELLULAR IMMUNITY; CHILD; CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOREGULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; TH1 CELL; TH17 CELL; TH2 CELL; TH3 CELL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; MALE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79961179668     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22984     Document Type: Article

References (40)

1. Cines DB. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 1923-1923.
2. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009; 113: 2386-2393.
3. Semple JW. Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev 2002; 16: 9-12.
4. Miossec P, Korn T, Kuchroo VK. Mechanisms of disease: Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-898.
5. Panitsas FP, Theodoropoulou M, Kouraklis A, et al. Brief report - Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 2004; 103: 2645-2647.
6. Wang TT, Zhao H, Ren H, et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 2005; 90: 914-923.
7. Ogawara H, Handa H, Morita K, et al. High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2003; 71: 283-288.
8. Webber NP, Mascarenhas JO, Crow MK, et al. Functional properties of lymphocytes in idiopathic thrombocytopenic purpura. Hum Immunol 2001; 62: 1346-1355.
9. Chen Y, Kuchroo VK, Inobe J, et al. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 1994; 265: 1237-1240.
10. Andersson PO, Stockelberg D, Jacobsson S, et al. A transforming growth factor-beta1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Ann Hematol 2000; 79: 507-513.
11. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4(+) effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132.
12. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.
13. Park H, Li ZX, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-1141.
14. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-748.
15. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116: 1310-1316.
16. Dardalhon V, Korn T, Kuchroo VK, et al. Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun 2008; 31: 252-256.
17. Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomy. Nat Med 2002; 8: 500-508.
18. Aarvak T, Chabaud M, Miossec P, et al. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999; 162: 1246-1261.
19. Teunissen MB, Koomen CW, de Waal Malefyt R, et al. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998; 111: 645-649.
20. Culic S, Labar B, Marusic A, et al. Correlations among age, cytokines, lymphocyte subtypes, and platelet counts in autoimmune thrombocytopenic purpura. Pediatr Blood Cancer 2006; 47: 671-674.
21. Andersson J. Cytokines in idiopathic thrombocytopenic purpura (ITP). Acta Paediatr Suppl 1998; 424: 61-64.
22. Mouzaki A, Theodoropoulou M, Gianakopoulos I, et al. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: Their role in prognosis. Blood 2002; 100: 1774-1779.
23. Semple JW, Milev Y, Cosgrave D, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: Relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996; 87: 4245-4254.
24. Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 2002; 141: 683-688.
25. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 2006; 133: 364-374.
26. Coopamah MD, Garvey MB, Freedman J, et al. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update. Transfus Med Rev 2003; 17: 69-80.
27. Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9: 1123-1124.
28. McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103: 1364-1369.
29. Emmerich F, Bal G, Barakat A, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2007; 136: 309-314.
30. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol 2000; 37: 239-248.
31. Roark JH, Bussel J, Cines DB, et al. Genetic analysis of autoantibodies in idiopathic thrombocytopenic-purpura reveals evidence of clonal expansion and somatic mutation. Blood 2002; 100: 1388-1398.
32. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16: 34-38.
33. Ferber IA, Brocke S, Taylor-Edwards C, et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996; 156: 5-7.
34. Korn T, Reddy J, Gao WD, et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007; 13: 423-431.
35. Guo ZX, Chen ZP, Zheng CL, et al. The role of Th17 cells in adult patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2009; 82: 488-489.
36. Ma DX, Zhu XJ, Zhao P, et al. Profile of Th17 cytokines (IL-17, TGF-beta, IL-6) and Th1 cytokine (IFN-gamma) in patients with immune thrombocytopenic purpura. Ann Hematol 2008; 87: 899-904.
37. Miller A, Lider O, Weiner HL. Antigen-driven bystander suppression after oral administration of antigens. J Exp Med 1991; 174: 791-798.
38. Weiner HL. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997; 7: 335-343.
39. Cross D, Cambier JC. Transforming growth factor beta 1 has differential effects on B cell proliferation and activation antigen expression. J Immunol 1990; 144: 432-439.
40. Bridoux F, Badou A, Saoudi A, et al. Transforming growth factor beta (TGF-beta)-dependent inhibition of T helper cell 2 (Th2)-induced autoimmunity by self-major histocompatibility complex (MHC) class II-specific, regulatory CD4(+) T cell lines. J Exp Med 1997; 185: 1769-1775.